Close Menu

More articles about Molecular Diagnostics

The agreement covers Kapa’s reagents for DNA amplification, sequencing, and molecular diagnostic applications.

Genomic Health will also hire additional sales people in connection with the launch, President and CEO Kim Popovits said yesterday at the JP Morgan Healthcare Conference.

The firms will use Qiagen's tools at WuXi's Shangai lab to offer biomarker services and to develop new markers.

Spain's Ferrer InCode will market BioTheranostics molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

The partnership will enable AIBioTech to use the Infiniti Analyzer and validated applications.

OncoDiagnostic is a CLIA-certified pathology and molecular diagnostics lab and will provide Predictive with a route to commercialize its molecular cancer diagnostic assays.

The firm has a confirmation hearing tomorrow with the US Bankruptcy Court for its reorganization plan.

Genetic Technologies will distribute the ResponseDX tests in Australia and in five SE Asian Nations.

Cepheid became the latest firm to receive an EUA for its H1N1 flu assay, but said it is the first to receive the designation for CLIA moderate complexity labs.

The Canadian firm, which already floats on the Toronto Stock Exchange, is gearing up for the launch of its LungExpress Dx product in the US.

Despite the recently soured economy, VCs have remained relatively optimistic about investment opportunities in the life science research tools and molecular diagnostics sectors, driven primarily by advances in nanotechnology, single-molecule genomics and proteomics techniques, and personalized medicine.

The private placement is subject to approval of Vermillion's reorganization plan by the US Bankruptcy Court.

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

Martell needs approximately $3 million in VC funds to develop a DNA-amplification and blood-based breast cancer diagnostic that is based on technology from the University of Pennsylvania.

The agreement to issue additional shares settles claims brought against Sequenom for alleged breach of representations and warranties made by Sequenom in its asset purchase agreement.

The firm has raised more than expected from the non-brokered direct placement of more than 5 million shares.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

The firm reported no revenues for the quarter, but it anticipates revenues of between $2 million and $4 million in 2010 tied to sales of its microRNA-based tests.

The companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the mutations for use in a possible diagnostic test.

Genomic Health has been conducting a number of studies to examine how well its RT-PCR-based Oncotype DX test compares to IHC and FISH for assessing the HER2 status of breast cancer patients.


According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.